Eli Lilly Invests $400 Million In Indianapolis, Indiana, Tech Center Enhancements
According to company officials, the plans are driven by increasing demand for Lilly's current medicines, and they provide additional manufacturing capacity for future medicines coming from Lilly's pipeline. These new investments will create approximately 100 new highly skilled jobs at the company. Eli Lilly also plans enhancements to existing manufacturing facilities that make insulin, additional capacity for its growing portfolio of diabetes medicines and initial capital investments for future medicines.
"These investments demonstrate Lilly's commitment to our manufacturing footprint in Indiana and the United States, and have been made possible by the tax reform measures passed by Congress in 2017," said David A. Ricks, Lilly's Chairman & CEO "With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production here at home. This is crucial for us to continue to advance our state's economy and drive future investment, adding high-tech jobs and facilities that keep Indiana competitive in the global marketplace."
"These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations," said Myles O'Neill, Senior Vice President & President of Manufacturing Operations. "All of these projects support Lilly's investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics."
O'Neill noted that in addition to increasing the capacity and capabilities needed to provide a safe and reliable supply of medicine for people, the investments also allow Lilly to add highly skilled U.S. manufacturing jobs. "To make medicine, we need highly skilled technicians, scientists and engineers, who are economic catalysts for local communities," he said.
"For decades, Indianapolis has been known as a hub for innovation, driven in large part by Eli Lilly and Company's commitment to our community and their global reputation as an industry leader," said Indianapolis Mayor Joe Hogsett. "Today's announcement helps to expand the skilled workforce in Indianapolis and reinforce the company's presence in central Indiana."
"Thanks to the long-standing commitment of companies like Lilly, Indiana is at the heart of global innovation and growth in life sciences, ranking No. 2 in the nation for total exports," said Indiana Secretary of Commerce Jim Schellinger. "We're excited to witness Lilly's continued success in central Indiana as the company invests $400 million at its Lilly Technology Center and continues to create quality career opportunities for Hoosiers. It is clear that Lilly will remain a staple in our state for many generations to come, serving customers around the world while giving back to the Indianapolis community here at home."
Lilly has invested over $5 billion in the United States since 2012, with the majority of this investment in its Indiana facilities and nearly $2 billion in manufacturing of diabetes medicines.
How are Uncertain Times Altering Company Location Strategies?
Infrastructure Investment as an Economic Stimulus Tool
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row